Improving screening for liver cancer
Prospective Comparison of Diagnostic Performance and Cost-effectiveness of US and Abbreviated MRI for Hepatocellular Carcinoma Screening
This study is testing whether a special type of MRI can find liver cancer better than regular ultrasound in people with chronic liver disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 330 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Lausanne Hospitals Academic / other |
| Locations | 1 site (Lausanne, Canton of Vaud) |
| Trial ID | NCT05828446 on ClinicalTrials.gov |
What this trial studies
This interventional study aims to compare the effectiveness of ultrasound versus abbreviated magnetic resonance imaging (AMRI) in detecting hepatocellular carcinoma (HCC) in patients with chronic liver disease. Participants will undergo screening rounds that include both ultrasound and MRI within the same week, conducted bi-annually. The study hypothesizes that AMRI with a contrast agent will yield a higher detection rate of HCC compared to routine ultrasound screenings.
Who should consider this trial
Good fit: Ideal candidates are adults with chronic liver disease who require HCC screening as per established guidelines.
Not a fit: Patients with a history of HCC, other malignancies, or those unsuitable for MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection of liver cancer, potentially enhancing patient outcomes.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in improving cancer detection rates using advanced imaging techniques.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All adult patients with chronic liver disease and indication for HCC screening according to the European Association for the Study of the Liver recommendations. * Informed Consent signed by the subject Exclusion Criteria: * History of HCC * History of other malignancy * Prior liver nodule categorized as LI-RAD 4, 5 or M * History of liver transplantation * Pregnancy * MRI or MRI contrast agent precaution * Any other condition making the patient unsuitable for the study * Patient's refusal of transmission of relevant medical conditions found on the medical examinations performed during the study
Where this trial is running
Lausanne, Canton of Vaud
- Lausanne University Hospital — Lausanne, Canton of Vaud, Switzerland (Recruiting)
Study contacts
- Principal investigator: Naik Vietti Violi, MD — University of Lausanne Hospitals
- Study coordinator: Naik Vietti Violi, MD
- Email: naik.vietti-violi@chuv.ch
- Phone: +41213144556
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.